PROTECT-Cog is a $100 million global trial that pairs structured lifestyle support with a metabolism-targeting drug to cut risk of decline, MCI and dementia. For people who have mild cognitive impairment, lifestyle support remains the actionable step because this trial tests prevention in at-risk adults, not MCI treatment.
PROTECT-Cog means Prevention of Risk fOr cogniTive dEcline through Combined Therapy. Mild cognitive impairment means memory or thinking changes are noticeable, yet daily independence remains. The Alzheimer's Association announced the $100 million trial on July 13, 2026, at AAIC in London, as described in its launch announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who PROTECT-Cog enrolls and how it compares care
- What structured lifestyle care has shown
- What semaglutide studies found in early Alzheimer's impairment
- What to do now if you have MCI
Who PROTECT-Cog enrolls and how it compares care
The trial will enroll older adults at increased risk for decline. It tests whether adding a GLP-1 or similar metabolism drug to multidomain lifestyle care further lowers risk of decline, MCI and dementia. Medical Daily reporting from AAIC described about three years of follow-up with cognitive and health checks every six months.
The comparison tests two lifestyle intensities while a subset also receives metabolic drug therapy. Medscape Medical News noted that the specific agent, dose, eligibility rules and sites were still being set at launch. Check official trial listings for current enrollment details once posted.
What structured lifestyle care has shown
U.S. POINTER was a two-year multisite trial in older at-risk adults. Both lifestyle groups improved cognition, and the structured, coached group improved more than the self-guided group.
The Alzheimer's Association reported in its POINTER results announcement that structured care protected against age-related decline. Structured care links several daily habits. Coaching provides a schedule, feedback and problem-solving.
- Exercise on most days, with aerobic plus strength work
- Heart-healthy eating pattern
- Cognitive and social activity each week
- Blood pressure, diabetes and cholesterol care
What semaglutide studies found in early Alzheimer's impairment
EVOKE and EVOKE+ tested daily oral semaglutide 14 mg in 3,808 adults ages 55 to 85 with MCI or mild dementia due to Alzheimer's. After 104 weeks, the drug did not slow decline on CDR-SB compared with placebo. Alzheimer Europe summarized the topline and CTAD presentation in its EVOKE results summary.
CDR-SB is a standard score of memory, thinking and daily function. That finding addresses treatment of existing impairment. PROTECT-Cog asks a different prevention question in at-risk adults.
What to do now if you have MCI
PROTECT-Cog focuses on prevention in at-risk adults. NeurologyLive noted in its prevention trial report that MCI care still centers on structured exercise, nutrition, cognitive and social activity, and vascular care. Ask your clinician about concrete next steps.
Focus the visit on habits, vascular risks and medications. Bring a medication list, recent labs and an activity log to that visit. That record helps tailor exercise, diet and vascular targets faster.
- Request a structured exercise and eating plan for heart and brain health
- Set weekly cognitive and social goals you will keep
- Review blood pressure, diabetes, cholesterol, medications and mood
- Discuss GLP-1 medicines only for approved uses, with review of benefits and side effects
You Might Also Like
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: A Source-Checked Research Briefing for People With Mild Cognitive Impairment
